Literature DB >> 30058217

Implementation of Pharmacogenetics at Cincinnati Children's Hospital Medical Center: Lessons Learned Over 14 Years of Personalizing Medicine.

Laura B Ramsey1,2,3, Cynthia A Prows4, Kejian Zhang5, Shannon N Saldaña6, Michael T Sorter3,7, John P Pestian3,8, Richard J Wenstrup9, Alexander A Vinks1,2,3, Tracy A Glauser3,10.   

Abstract

Entities:  

Mesh：

Year:  2018        PMID： 30058217      PMCID： PMC6312508          DOI： 10.1002/cpt.1165

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN： 0009-9236            Impact factor:   6.875


× No keyword cloud information.
  5 in total

Review 1.  Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response.

Authors:  J Kirchheiner; K Nickchen; M Bauer; M-L Wong; J Licinio; I Roots; J Brockmöller
Journal:  Mol Psychiatry       Date:  2004-05       Impact factor: 15.992

Review 2.  Pharmacogenetics-based new therapeutic concepts.

Authors:  Ivar Roots; Thomas Gerloff; Christian Meisel; Julia Kirchheiner; Mark Goldammer; Rolf Kaiser; Gabriele Laschinski; Jürgen Brockmöller; Ingolf Cascorbi; Ullrich Kleeberg; Alfred G Hildebrandt
Journal:  Drug Metab Rev       Date:  2004-10       Impact factor: 4.518

3.  Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for codeine therapy in the context of cytochrome P450 2D6 (CYP2D6) genotype.

Authors:  K R Crews; A Gaedigk; H M Dunnenberger; T E Klein; D D Shen; J T Callaghan; E D Kharasch; T C Skaar
Journal:  Clin Pharmacol Ther       Date:  2011-12-28       Impact factor: 6.875

Review 4.  Genetic variability of drug-metabolizing enzymes: the dual impact on psychiatric therapy and regulation of brain function.

Authors:  J C Stingl; J Brockmöller; R Viviani
Journal:  Mol Psychiatry       Date:  2012-05-08       Impact factor: 15.992

Review 5.  Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450 2D6 genotype and codeine therapy: 2014 update.

Authors:  K R Crews; A Gaedigk; H M Dunnenberger; J S Leeder; T E Klein; K E Caudle; C E Haidar; D D Shen; J T Callaghan; S Sadhasivam; C A Prows; E D Kharasch; T C Skaar
Journal:  Clin Pharmacol Ther       Date:  2014-01-23       Impact factor: 6.875
  5 in total
  24 in total

Review 1.  Pediatric pharmacogenomics: challenges and opportunities: on behalf of the Sanford Children's Genomic Medicine Consortium.

Authors:  David Gregornik; Daria Salyakina; Marilyn Brown; Samuel Roiko; Kenneth Ramos
Journal:  Pharmacogenomics J       Date:  2020-08-26       Impact factor: 3.550

2.  Challenges and lessons learned from clinical pharmacogenetic implementation of multiple gene-drug pairs across ambulatory care settings.

Authors:  Emily J Cicali; Kristin Wiisanen Weitzel; Amanda R Elsey; Frank A Orlando; Michelle Vinson; Scott Mosley; D Max Smith; Richard Davis; Lori Drum; David Estores; James P Franciosi; Melanie Gross Hagen; Gabriel J Jerkins; Elvira S Mercado; Jaison Nainaparampil; Adaixa Padron; Eric I Rosenberg; Ashleigh Wright; Siegfried O Schmidt; Carol A Mathews; Larisa H Cavallari; Julie A Johnson
Journal:  Genet Med       Date:  2019-03-30       Impact factor: 8.822

3.  Providers' perspectives on the clinical utility of pharmacogenomic testing in pediatric patients.

Authors:  Ina Liko; Yee Ming Lee; Danielle L Stutzman; Allison B Blackmer; Kimberly M Deininger; Ann M Reynolds; Christina L Aquilante
Journal:  Pharmacogenomics       Date:  2021-03-04       Impact factor: 2.533

4.  The Value of Pharmacogenetics to Reduce Drug-Related Toxicity in Cancer Patients.

Authors:  Doreen Z Mhandire; Andrew K L Goey
Journal:  Mol Diagn Ther       Date:  2022-02-03       Impact factor: 4.074

5.  CYP2D6 Phenotype Influences Aripiprazole Tolerability in Pediatric Patients with Mood Disorders.

Authors:  Sahar A Jallaq; Mark Verba; Jeffrey R Strawn; Lisa J Martin; Melissa P DelBello; Laura B Ramsey
Journal:  J Child Adolesc Psychopharmacol       Date:  2020-08-25       Impact factor: 2.576

6.  Clinical Utility of Pharmacogenomic Data Collected by a Health-System Biobank to Predict and Prevent Adverse Drug Events.

Authors:  Sonam N Shah; Roseann S Gammal; Mary G Amato; Maryam Alobaidly; Dariel Delos Reyes; Sarah Hasan; Diane L Seger; Joel B Krier; David W Bates
Journal:  Drug Saf       Date:  2021-02-23       Impact factor: 5.606

Review 7.  Pharmacogenomics in the United States Community Pharmacy Setting: The Clopidogrel-CYP2C19 Example.

Authors:  David F Kisor; Natasha J Petry; David R Bright
Journal:  Pharmgenomics Pers Med       Date:  2021-05-18

8.  Assessment of the Implementation of Pharmacogenomic Testing in a Pediatric Tertiary Care Setting.

Authors:  Iris Cohn; Roozbeh Manshaei; Eriskay Liston; John B A Okello; Reem Khan; Meredith R Curtis; Abby J Krupski; Rebekah K Jobling; Kelsey Kalbfleisch; Tara A Paton; Miriam S Reuter; Robin Z Hayeems; Ruud H J Verstegen; Aaron Goldman; Raymond H Kim; Shinya Ito
Journal:  JAMA Netw Open       Date:  2021-05-03

9.  Implementing Pharmacogenomics Testing: Single Center Experience at Arkansas Children's Hospital.

Authors:  Pritmohinder S Gill; Feliciano B Yu; Patricia A Porter-Gill; Bobby L Boyanton; Judy C Allen; Jason E Farrar; Aravindhan Veerapandiyan; Parthak Prodhan; Kevin J Bielamowicz; Elizabeth Sellars; Andrew Burrow; Joshua L Kennedy; Jeffery L Clothier; David L Becton; Don Rule; G Bradley Schaefer
Journal:  J Pers Med       Date:  2021-05-11

10.  Independent Community Pharmacists' Experience in Offering Pharmacogenetic Testing.

Authors:  Susanne B Haga; Rachel Mills; Jivan Moaddeb; Yiling Liu; Deepak Voora
Journal:  Pharmgenomics Pers Med       Date:  2021-07-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.